G1 Therapeutics Inc (NAS:GTHX)
$ 7.15 0 (0%) Market Cap: 377.22 Mil Enterprise Value: 364.45 Mil PE Ratio: 0 PB Ratio: 15.31 GF Score: 31/100

G1 Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 10, 2020 / 12:30PM GMT
Release Date Price: $16.67 (+7.93%)
Mark A. Velleca
G1 Therapeutics, Inc. - CEO, President & Director

Okay. I'll get started. Appreciate the opportunity to share the G1 story in this virtual conference, and want to thank the organizers at Barclays and Peter Lawson, who, I know, will be joining for the Q&A. We do have an abbreviated deck posted on our website as well as our latest corporate overview. I'll just make a few high-level comments and then go to Q&A.

We're a clinical stage oncology company. We were founded by Dr. Ned Sharpless when he was Head of the Cancer Center at UNC. He's currently Director of the National Cancer Institute. We went public in 2017, and we've advanced 3 therapeutic candidates from preclinical to meaningful clinical data and are looking at the first approval of our lead program, trilaciclib, as we file an NDA in 2020. A very experienced team, an independent Board of Directors, and we're headquartered here in Research Triangle Park, North Carolina.

We're advancing 3 innovative therapeutic candidates, the lead, trilaciclib, which is our first-in-class myelopreservation therapy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot